This article is more than 5 years old. Information may no longer be current.
Glaukos licenses Intratus’ cream-based drug delivery system
Glaukos and Intratus have entered into a licensing agreement for Intratus’ noninvasive drug delivery platform, according to a press release.
Intratus’ cream-based drug formulations, designed for use in the treatment of dry eye disease, glaucoma and other corneal disorders, are applied to the outer surface of the eyelid for transdermal delivery.
Under the terms of the agreement Glaukos will have global exclusive rights to research, develop, manufacture and commercialize the platform.
“This licensing agreement adds a novel drug delivery platform using a differentiated, noninvasive transdermal approach to our expanding portfolio of sustained pharmaceutical systems,” Thomas Burns, Glaukos president and CEO, said in the release. “Intratus’ proprietary transdermal drug delivery application is highly complementary to our expanding portfolio of sustained pharmaceutical systems and represents a synergistic fit with our glaucoma and corneal health R&D initiatives. With this agreement, we plan to build upon the promising development work Intratus has completed to advance this exciting new drug delivery approach into the appropriate clinical phases.”
Financial terms of the agreement were not disclosed.